Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 14/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.69 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12332479 | 1.00 | ADORA1 (0.69) | ADORA1ADORA3ADORA2ACYP2D6ADORA2B | |
| SCHEMBL15061400 | 1.00 | ADORA1 (0.69) | ADORA1ADORA3ADORA2ACYP2D6ADORA2B | |
| SCHEMBL12226386 | 1.00 | ADORA1 (0.69) | ADORA1ADORA3ADORA2ACYP2D6ADORA2B | |
| SCHEMBL12200119 | 1.00 | ADORA1 (0.69) | ADORA1ADORA3ADORA2ACYP2D6ADORA2B | |
| SCHEMBL15425649 | 1.00 | ADORA1 (0.69) | ADORA1ADORA3ADORA2ACYP2D6ADORA2B | |
| SCHEMBL15061399 | 1.00 | ADORA1 (0.69) | ADORA1ADORA3ADORA2ACYP2D6ADORA2B | |
| SCHEMBL16575066 | 1.00 | ADORA1 (0.69) | ADORA1ADORA3ADORA2ACYP2D6ADORA2B | |
| SCHEMBL15426676 | 0.88 | ADORA1 (0.55) | ADORA1ADORA3ADORA2ACYP2D6ADORA2B | |
| SCHEMBL15425654 | 0.88 | ADORA1 (0.55) | ADORA1ADORA3ADORA2ACYP2D6ADORA2B | |
| SCHEMBL6660666 | 0.86 | ADORA3 (0.79) | ADORA1ADORA3ADORA2ACYP2D6ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158268-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-8895530-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158268-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE3A, PDE2A, PDE6C | ADORA1 18/4885ADORA3 31/4885ADORA2A 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.